RASHIDAT LAIYEMO: Open Payments
NPI 1144825613 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$333 in 13 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $333
Food & beverage: $333
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $100 |
| GENZYME CORPORATION | 2 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| BioCryst US Sales Co., LLC | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: DUPIXENT, Rhapsido, ORLADEYO, DAWNZERA, NEFFY, FASENRA.
Industry payments across MD — which companies pay providers there.
